Literature DB >> 28082076

Topical bisphosphonate augments fixation of bone-grafted hydroxyapatite coated implants, BMP-2 causes resorption-based decrease in bone.

Jorgen Baas1, Marianne Vestermark1, Thomas Jensen1, Joan Bechtold2, Kjeld Soballe1, Thomas Jakobsen3.   

Abstract

Bone allograft is used in total joint arthroplasties in order to enhance implant fixation. BMPs are known to stimulate new bone formation within allograft, but also known to accelerate graft resorption. Bisphosphonates are strong inhibitor of bone resorption. The aim of this study was to investigate whether the bisphosphonate zoledronate was able to counteract the accelerated graft resorption without interfering with the BMP induced bone formation. In the present study the two drugs alone and in combination were studied in our canine model of impaction bone grafting. We included 10 dogs in this study. Cancellous allograft bone grafts were soaked in either saline or zoledronate solution (0.005mg/mL) and then vehicle or BMP2 (0.15mg rhBMP2) was added. This produced four treatment groups: A) control, B) BMP2, C) zoledronate and D) BMP2+zoledronate. The allograft treated with A, B, C or D was impacted into a circumferential defect of 2.5mm around HA-coated porous Ti implants. Each dog received all four treatment groups with two implants in the distal part of each femur. The group with allograft soaked in zoledronate (C) showed better biomechanical fixation than all other groups (p<0.05). It had less allograft resorption compared to all other groups (p<0.005) without any statistically significant change in new bone formation. The addition of BMP2 to the allograft did not increase new bone formation significantly, but did accelerate allograft resorption. This was also the case where the allograft was treated with BMP2 and zoledronate in combination (D). This caused a decrease in mechanical implant fixation in both these groups compared to the control group, however only statistically significant for the BMP2 group compared to control. The study shows that topical zoledronate can be a valuable tool for augmenting bone grafts when administered optimally. The use of BMP2 in bone grafting procedures seems associated with a high risk of bone resorption and mechanical weakening.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Allograft; Bisphosphonate; Bone morphogenetic protein; Implant fixation; Joint replacement

Mesh:

Substances:

Year:  2017        PMID: 28082076      PMCID: PMC5367933          DOI: 10.1016/j.bone.2017.01.007

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  29 in total

1.  The use of OP-1 in femoral impaction grafting in a sheep model.

Authors:  Margaret A McGee; David M Findlay; Donald W Howie; Angelo Carbone; Peter Ward; Roumen Stamenkov; Tara T Page; Warrick J Bruce; Corinna I Wildenauer; Carol Toth
Journal:  J Orthop Res       Date:  2004-09       Impact factor: 3.494

2.  Interspecies differences in bone composition, density, and quality: potential implications for in vivo bone research.

Authors:  J Aerssens; S Boonen; G Lowet; J Dequeker
Journal:  Endocrinology       Date:  1998-02       Impact factor: 4.736

3.  Bone allografts pretreated with a bisphosphonate are not resorbed.

Authors:  Per Aspenberg; Jörgen Astrand
Journal:  Acta Orthop Scand       Date:  2002-01

Review 4.  Bone morphogenetic protein (BMP) for fracture healing in adults.

Authors:  Kimberly R Garrison; Ian Shemilt; Simon Donell; Jonathan J Ryder; Miranda Mugford; Ian Harvey; Fujian Song; Volker Alt
Journal:  Cochrane Database Syst Rev       Date:  2010-06-16

5.  Manipulation of the anabolic and catabolic responses with OP-1 and zoledronic acid in a rat critical defect model.

Authors:  David G Little; Michelle McDonald; Rick Bransford; Craig B Godfrey; Negin Amanat
Journal:  J Bone Miner Res       Date:  2005-07-18       Impact factor: 6.741

6.  Mixing bone graft with OP-1 does not improve cup or stem fixation in revision surgery of the hip: 5-year follow-up of 10 acetabular and 11 femoral study cases and 40 control cases.

Authors:  Johan Kärrholm; Patrick Hourigan; John Timperley; Reza Razaznejad
Journal:  Acta Orthop       Date:  2006-02       Impact factor: 3.717

Review 7.  Hydroxyapatite ceramic coating for bone implant fixation. Mechanical and histological studies in dogs.

Authors:  K Søballe
Journal:  Acta Orthop Scand Suppl       Date:  1993

8.  The effect of pretreating morselized allograft bone with rhBMP-2 and/or pamidronate on the fixation of porous Ti and HA-coated implants.

Authors:  Jorgen Baas; Brian Elmengaard; Thomas B Jensen; Thomas Jakobsen; Niels T Andersen; Kjeld Soballe
Journal:  Biomaterials       Date:  2008-04-14       Impact factor: 12.479

Review 9.  Adjuvant therapies of bone graft around non-cemented experimental orthopedic implants stereological methods and experiments in dogs.

Authors:  Jørgen Baas
Journal:  Acta Orthop Suppl       Date:  2008-08

10.  Local treatment of cancellous bone grafts with BMP-7 and zoledronate increases both the bone formation rate and bone density: a bone chamber study in rats.

Authors:  Ola Belfrage; Gunnar Flivik; Martin Sundberg; Uldis Kesteris; Magnus Tägil
Journal:  Acta Orthop       Date:  2011-03-24       Impact factor: 3.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.